Literature DB >> 10092150

Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread.

H Renneberg1, A Friedetzky, L Konrad, R Kurek, K Weingärtner, G Wennemuth, U W Tunn, G Aumüller.   

Abstract

Detection of prostate-specific membrane antigen (PSM)-mRNA expression in blood samples using reverse transcription polymerase chain reaction (RT-PCR) is discussed as a new diagnostic marker of circulating micrometastases in prostate cancer patients. We applied the RT-PCR technique to different human tissues and obtained positive signals for PSM transcripts in human genital and multiple extra-genital tissue sites. The cDNAs were prepared from different human tissues and prostatic cell lines. RT-PCR and nested RT-PCR for PSM was performed with primers derived from the published PSM cDNA. The RT-PCR fragments obtained were cloned and showed 100% sequence homology to PSM. Southern blot hybridization with labeled probes was used to confirm the specificity of the amplicons. In addition to the known PSM expression in the human brain, PSM-mRNA was detected in cDNA isolated from human testis, epididymis and seminal vesicles and in the PC-3 prostatic cancer cell line. Furthermore, we found PSM-mRNA in heart, liver, lung, kidney, spleen, and thyroid gland. The results indicate that PSM expression is not restricted to the prostate gland, but represents a more general component of genital and extra-genital human tissues. This must be considered when RT-PCR and nested RT-PCR screening for PSM expression is performed as a diagnostic measure in blood from prostate cancer patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092150     DOI: 10.1007/s002400050085

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  5 in total

1.  Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts non-organ confined disease in radical prostatectomy specimens.

Authors:  John Varkarakis; Charalambos Deliveliotis; Diamandis Sideris; Nikolaos Trakas; Aris Giannopoulos
Journal:  Urol Res       Date:  2003-04-23

2.  Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.

Authors:  Hanjun Qin; Chunxia Zhou; Dongmei Wang; Wenbo Ma; Xiao Liang; Chen Lin; Youhui Zhang; Shuren Zhang
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

3.  SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.

Authors:  Marcella Fassò; Rebecca Waitz; Yafei Hou; Tae Rim; Norman M Greenberg; Nilabh Shastri; Lawrence Fong; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-26       Impact factor: 11.205

4.  Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells.

Authors:  Lutz Konrad; Jonas A Scheiber; Elke Völck-Badouin; Marcel M Keilani; Leslie Laible; Heidrun Brandt; Ansgar Schmidt; Gerhard Aumüller; Rainer Hofmann
Journal:  BMC Genomics       Date:  2007-09-11       Impact factor: 3.969

5.  DUP1 peptide modified micelle efficiently targeted delivery paclitaxel and enhance mitochondrial apoptosis on PSMA-negative prostate cancer cells.

Authors:  Haining Chen; Fengbo Wu; Jing Li; Xuehua Jiang; Lulu Cai; Xiang Li
Journal:  Springerplus       Date:  2016-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.